• Product NameTrametinib (GSK1120212)
• Brief DescriptionInhibitors
• Purification99.39%
• Biological ActivityTrametinib is an orally bioavailable inhibitor of mitogen-activated protein kinase kinase (MEK MAPK/ERK kinase) with potential antineoplastic activity. Trametinib specifically binds to and inhibits MEK 1 and 2, resulting in an inhibition of growth factor-mediated cell signaling and cellular proliferation in various Ys. MEK 1 and 2, dual specificity threonine/tyrosine kinases often upregulated in various Y cell types, play a key role in the activation of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth.
• Target NameMEK inhibitor
• CAS No. 871700-17-3
• Calculated MW 615.39
• Formulation C26H23FIN5O4
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cancer
  SMILES:CN1C(=O)C(C)=C2N(C(=O)N(C3CC3)C(=O)C2=C1NC1=C(F)C=C(I)C=C1)C1=CC(NC(C)=O)=CC=C1
  Pathways:MAPK
  Receptor:MEK1; MEK2
  Boling pt:
  Melting pt:
  Solubility:DMSO: 22 mg/mL warmed (35.74 mM)
  Appearance:White Powder
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Yamaguchi T, et al. Int J Oncol, 2011, 39(1), 23-31.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting